BCAX — Bicara Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023658 ·
Last close
$21.98
Market Cap
$1.44B
52W High
$24.25
52W Low
$16.12
ADV30
509,295
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -60,242,000 | -56,211,000 | 553,599,000 | 323,462,000 | 39,641,000 |
| Dec 2025 | 0 | — | -41,122,000 | -37,386,000 | 430,994,000 | 96,685,000 | 29,542,000 |
| Sep 2025 | 0 | — | -40,676,000 | -36,330,000 | 424,688,000 | 171,673,000 | 21,908,000 |
| Jun 2025 | 0 | — | -32,018,000 | -27,388,000 | 453,587,000 | 436,606,000 | 18,391,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-106,834,000
Investing CF
$-318,453,000
Financing CF
$32,261,000
CapEx
$-286,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.53
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-358,966,000
Inventory
—
Receivables
—
ST Investments
$318,116,000
EBIT TTM
$-155,604,000
Pretax Income TTM
$-137,733,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -155,604,000 | -137,950,000 | 430,994,000 | 29,542,000 | — | -106,834,000 |
| Dec 2024 | 0 | -82,389,000 | -67,995,000 | 509,996,000 | 18,121,000 | — | -74,751,000 |
| Dec 2023 | 0 | -39,889,000 | -51,985,000 | 233,982,000 | 382,751,000 | — | -45,628,000 |
| Dec 2022 | 0 | -37,656,000 | -37,845,000 | 6,703,000 | 105,506,000 | — | -32,076,000 |
TTM Snapshot
Revenues TTM
$3,160,000
NetIncome TTM
$-40,326,000
OpCashFlow TTM
$0
Assets (Latest)
$509,996,000
Forward EPS
$-3.63
Max Pain — expiry 2026-06-18
max pain strike: $20.00 · spot: $21.98 · call oi: 569 · put oi: 645
Expected Move to 2026-06-18:
±$5.55
(25.25%) —
implied range
$16.43 –
$27.53
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| URGN | UroGen Pharma Ltd. | $1.44B | $29.46 | — |
| KALV | KalVista Pharmaceuticals, Inc. | $1.43B | $26.81 | — |
| PRGO | PERRIGO Co plc | $1.49B | $10.80 | — |
| SEPN | Septerna, Inc. | $1.38B | $30.65 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.51B | $8.12 | — |
News headlines (Yahoo Finance, 1h cache)
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
2026-05-22 15:09 · Yahoo
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
2026-05-21 21:00 · Yahoo
A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback
2026-05-19 13:09 · Yahoo
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
2026-05-15 23:02 · Yahoo
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 22:56 · Yahoo
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
2026-05-14 21:09 · Yahoo
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2026-05-13 12:30 · Yahoo
Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...
2026-05-12 07:03 · Yahoo
Bicara Therapeutics Inc. Common Stock Q1 2026 Earnings Call Summary
2026-05-11 20:51 · Yahoo
Bicara Therapeutics Q1 Earnings Call Highlights
2026-05-11 14:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.